A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT03526835. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors
Study identification
- NCT ID
- NCT03526835
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Merus B.V.
- Industry
- Enrollment
- 523 participants
Conditions and interventions
Conditions
Interventions
- MCLA-158 Drug
- MCLA-158 + Pembrolizumab Combination Product
- MCLA-158 + FOLFIRI Combination Product
- MCLA-158 + FOLFOX Combination Product
Drug · Combination Product
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 1, 2018
- Primary completion
- Oct 31, 2025
- Completion
- Oct 31, 2027
- Last update posted
- Jan 28, 2025
2018 – 2027
United States locations
- U.S. sites
- 23
- U.S. states
- 13
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSD | La Jolla | California | 92093 | Recruiting |
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | Recruiting |
| Sharp Healthcare | San Diego | California | 92123 | Recruiting |
| Rocky Mountain Cancer Centers | Lone Tree | Colorado | 80124 | Recruiting |
| Florida Cancer Specialists | Fort Myers | Florida | 33901 | Recruiting |
| Sarah Cannon Research Institute (Lake Nona) | Orlando | Florida | 32827 | Recruiting |
| Massachusetts General Hospital - Dana Farber | Boston | Massachusetts | 02114 | Recruiting |
| SSM Health Saint Louis University Hospital | St Louis | Missouri | 63110 | Recruiting |
| Washington University School of Medicine at St Louis | St Louis | Missouri | 63110 | Recruiting |
| Cayuga Medical Center | Ithaca | New York | 14850 | Recruiting |
| Hematology-Oncology Associates of Central New York | Syracuse | New York | 13057 | Recruiting |
| Cleveland Clinic | Cleveland | Ohio | 44195 | Recruiting |
| Taylor Cancer Research Center | Maumee | Ohio | 43537 | Recruiting |
| SSM OKC Hightower Clinical | Oklahoma City | Oklahoma | 73102 | Recruiting |
| The University Of Tennessee Health Science Center | Memphis | Tennessee | 38103 | Recruiting |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | Completed |
| Texas Oncology | Dallas | Texas | 75246 | Recruiting |
| Oncology Consultants | Houston | Texas | 77030 | Recruiting |
| Texas Oncology | Tyler | Texas | 75702 | Recruiting |
| Utah Cancer Specialists | Salt Lake City | Utah | 84106 | Recruiting |
| University of Utah Health Huntsman Cancer Hospital | Salt Lake City | Utah | 84112 | Recruiting |
| Oncology & Hematology Associates of Southwest Virginia | Roanoke | Virginia | 24014 | Recruiting |
| Cancer Care Northwest | Spokane | Washington | 99202 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03526835, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 28, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03526835 live on ClinicalTrials.gov.